Roche Holding AG (RHHBY) Research

Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.

Market snapshot

Symbol
RHHBY
Price
$49.74
Day change
-2.59%
Market cap
$254.6B
P/E ratio
19.77x
52-week range
37.51-60.85
Sector
Healthcare
Industry
Drug Manufacturers - General
Next earnings
in 1 month
Analyst price target
$52.50

Recent news

  • FDA approves first generic version of Roche's flu drug

    The U.S. Food and Drug Administration approved the first generic version of ​Roche's Xofluza, a single-dose flu medicine for ‌certain patients aged five years and older, the regulator said on Wednesday.

  • Roche sticks to German investment after Eli Lilly cuts

    The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its ​planned investments in Germany, unlike some of ‌its competitors that have scaled back spending in the country.

  • This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

    Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.

Peer companies

  • AstraZeneca PLC (AZNCF)
  • Chugai Pharmaceutical Co., Ltd. (CHGCF)
  • Chugai Pharmaceutical Co., Ltd. (CHGCY)
  • Daiichi Sankyo Company, Limited (DSKYF)
  • Daiichi Sankyo Company, Limited (DSNKY)
  • GSK plc (GLAXF)
  • Novo Nordisk A/S (NONOF)
  • Novartis AG (NVSEF)

Open Roche Holding AG (RHHBY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.